Business
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE--(BUSINESS
About this update from Omeros Corporation
[{"type":"text","content":"\n-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --\n\n\n SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.\n\n\nThe abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at ehaweb.org. Details of the congress presentations are found below.\n\n\nOMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)\nSession Name: s454 Clinical and translational in bone marrow failure syndromes and PNH\nDate: Saturday, June 15, 2024\nPodium Presentation Session Time: 4:30 p.m. CEST\nLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102\nPresenting Author: Morag Griffin MBChB, FRCPath\n\n\nClinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)\nDate: Friday, June 14, 2024\nPresentation Time: 6:00 p.m. - 7:00 p.m. CEST\nLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7\nPresenting Author: William Pullman MB BS, PhD, FRACP\n\n\nExposure-Response Modeling Using Population PK/PD Methods Reliably Predict Population and Individual Responses of Complement Mature Factor D, Hemoglobin and LDH in PNH Patients Exposed to OMS906 (Abstract #P1920)\nDate: Friday, June 14, 2024\nLocation: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7\nPresenting Author: William Pullman MB BS, PhD, FRACP\n\n\nThe presentation materials associated with each abstract will be made available on Omeros’ website at www.omeros.com following the congress presentations.\n\n\nAbout OMS906\n\n\nOMS906 is an investigational humanized monoclonal antibody targetin...